Wellington Management Group’s Fulcrum Therapeutics FULC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-285,084
Closed -$1.04M – 1953
2026
Q2
$1.04M Buy
285,084
+166,484
+140% +$1.01M ﹤0.01% 1743
2026
Q1
$910K Sell
118,600
-27,827
-19% -$258K ﹤0.01% 1690
2025
Q4
$1.66M Sell
146,427
-32,931
-18% -$335K ﹤0.01% 1636
2025
Q3
$1.65M Buy
179,358
+52,956
+42% +$383K ﹤0.01% 1682
2025
Q2
$870K Buy
+126,402
New +$676K ﹤0.01% 1738
2025
Q1
– Sell
-172,158
Closed -$809K – 1985
2024
Q4
$809K Sell
172,158
-4,003
-2% -$14.8K ﹤0.01% 1756
2024
Q3
$629K Sell
176,161
-6,568
-4% -$48.7K ﹤0.01% 1788
2024
Q2
$1.13M Buy
182,729
+10,069
+6% +$76.3K ﹤0.01% 1648
2024
Q1
$1.63M Buy
+172,660
New +$1.54M ﹤0.01% 1571

Other funds holding FULC

Wellington Management Group's FULC Position: Q3 2026 in Review

Wellington Management Group sold out of Fulcrum Therapeutics (FULC) in Q3 2026, closing a stake of 285,084 shares — an estimated $1.04M sold.

Wellington Management Group first reported a position in FULC in Q1 2024 and held it in 9 quarters. The position peaked at $1.66M in Q4 2025. 151 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Wellington Management Group reported no remaining Fulcrum Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Wellington Management Group sold 285,084 Fulcrum Therapeutics shares in Q3 2026, an estimated $1.04M.
  • Wellington Management Group first reported a position in Fulcrum Therapeutics in Q1 2024 and held it in 9 quarters.
  • Wellington Management Group's Fulcrum Therapeutics position peaked at $1.66M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.